Savara Inc (NASDAQ:SVRA) Sees Large Growth in Short Interest

Savara Inc (NASDAQ:SVRAGet Free Report) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 5,640,000 shares, a growth of 25.3% from the May 15th total of 4,500,000 shares. Based on an average daily trading volume, of 877,400 shares, the short-interest ratio is presently 6.4 days. Currently, 7.8% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SVRA. Evercore ISI dropped their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, May 16th. Piper Sandler increased their price target on shares of Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Savara in a report on Monday, May 13th. JMP Securities reiterated a “market outperform” rating and set a $8.00 target price on shares of Savara in a research note on Monday, May 6th. Finally, Oppenheimer lifted their target price on Savara from $9.50 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, May 21st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $9.17.

View Our Latest Report on Savara

Savara Stock Performance

SVRA stock traded up $0.02 on Friday, hitting $4.08. The company had a trading volume of 681,323 shares, compared to its average volume of 921,826. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. Savara has a 12-month low of $2.60 and a 12-month high of $5.70. The stock has a market cap of $563.82 million, a price-to-earnings ratio of -11.03 and a beta of 0.70. The stock’s 50-day simple moving average is $4.52 and its 200 day simple moving average is $4.64.

Savara (NASDAQ:SVRAGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, equities research analysts expect that Savara will post -0.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co bought a new position in shares of Savara in the 1st quarter worth approximately $35,000. AJOVista LLC bought a new stake in Savara during the fourth quarter valued at approximately $40,000. Principal Financial Group Inc. purchased a new stake in Savara during the third quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. bought a new position in Savara in the fourth quarter worth approximately $74,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Savara by 665.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock worth $92,000 after acquiring an additional 16,959 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.